Kotaro Haruhara

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8099404/publications.pdf

Version: 2024-02-01

		516215	676716
55	645	16	22
papers	citations	h-index	g-index
55	55	55	822
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Glomerular Density and Volume in Renal Biopsy Specimens of Children with Proteinuria Relative to Preterm Birth and Gestational Age. Clinical Journal of the American Society of Nephrology: CJASN, 2017, 12, 585-590.	2.2	47
2	Adipocyteâ€Specific Enhancement of Angiotensin II Type 1 Receptorâ€Associated Protein Ameliorates Dietâ€Induced Visceral Obesity and Insulin Resistance. Journal of the American Heart Association, 2017, 6,	1.6	32
3	An angiotensin II type 1 receptor binding molecule has a critical role in hypertension in a chronic kidney disease model. Kidney International, 2017, 91, 1115-1125.	2.6	30
4	Angiotensin II Type 1 Receptorâ€Associated Protein Regulates Kidney Aging and Lifespan Independent of Angiotensin. Journal of the American Heart Association, 2017, 6, .	1.6	30
5	Biopsy-based estimation of total nephron number in Japanese living kidney donors. Clinical and Experimental Nephrology, 2019, 23, 629-637.	0.7	30
6	Factors associated with a vicious cycle involving a low nephron number, hypertension and chronic kidney disease. Hypertension Research, 2015, 38, 633-641.	1.5	27
7	Improved home BP profile with dapagliflozin is associated with amelioration of albuminuria in Japanese patients with diabetic nephropathy: the Yokohama add-on inhibitory efficacy of dapagliflozin on albuminuria in Japanese patients with type 2 diabetes study (Y-AIDA study). Cardiovascular Diabetology, 2019, 18, 110.	2.7	27
8	Glomerulopathy Associated With Moderate Obesity. Kidney International Reports, 2016, 1, 250-255.	0.4	23
9	Renal histopathological findings in relation to ambulatory blood pressure in chronic kidney disease patients. Hypertension Research, 2015, 38, 116-122.	1.5	22
10	Estimation of nephron number in living humans by combining unenhanced computed tomography with biopsy-based stereology. Scientific Reports, 2019, 9, 14400.	1.6	21
11	Early Enhanced Leucine-Rich $\langle i \rangle \hat{l} \pm \langle i \rangle$ -2-Glycoprotein-1 Expression in Glomerular Endothelial Cells of Type 2 Diabetic Nephropathy Model Mice. BioMed Research International, 2018, 2018, 1-9.	0.9	19
12	Glomerular Density in Biopsy-Proven Hypertensive Nephrosclerosis. American Journal of Hypertension, 2015, 28, 1164-1171.	1.0	18
13	Bowman Capsule Volume and Related Factors in Adults With Normal Renal Function. Kidney International Reports, 2018, 3, 314-320.	0.4	18
14	Renal Tubule Angiotensin II Type 1 Receptor–Associated Protein Promotes Natriuresis and Inhibits Saltâ€Sensitive Blood Pressure Elevation. Journal of the American Heart Association, 2015, 4, e001594.	1.6	17
15	Angiotensin II Type 1 Receptor-associated Protein Inhibits Angiotensin II-induced Insulin Resistance with Suppression of Oxidative Stress in Skeletal Muscle Tissue. Scientific Reports, 2018, 8, 2846.	1.6	17
16	Effects of rikkunshito on renal fibrosis and inflammation in angiotensin II-infused mice. Scientific Reports, 2019, 9, 6201.	1.6	17
17	Single-Nephron GFR in Patients With Obesity-Related Glomerulopathy. Kidney International Reports, 2020, 5, 1218-1227.	0.4	17
18	Angiotensin II Type 1 Receptor Binding Molecule ATRAP as a Possible Modulator of Renal Sodium Handling and Blood Pressure in Pathophysiology. Current Medicinal Chemistry, 2015, 22, 3210-3216.	1.2	16

#	Article	IF	Citations
19	Dietary Protein Intake and Single-Nephron Glomerular Filtration Rate. Nutrients, 2020, 12, 2549.	1.7	13
20	Podometrics in Japanese Living Donor Kidneys: Associations with Nephron Number, Age, and Hypertension. Journal of the American Society of Nephrology: JASN, 2021, 32, 1187-1199.	3.0	13
21	Synergistic Impact of Diabetes and Hypertension on the Progression and Distribution of Glomerular Histopathological Lesions. American Journal of Hypertension, 2019, 32, 900-908.	1.0	12
22	Volume Ratio of Glomerular Tufts to Bowman Capsules and Renal Outcomes in Nephrosclerosis. American Journal of Hypertension, 2019, 32, 45-53.	1.0	12
23	Assessment of nephron number and single-nephron glomerular filtration rate in a clinical setting. Hypertension Research, 2021, 44, 605-617.	1.5	12
24	Reduction of proteinuria by therapeutic intervention improves the renal outcome of elderly patients with IgA nephropathy. Clinical and Experimental Nephrology, 2016, 20, 910-917.	0.7	10
25	Angiotensin receptor-binding molecule in leukocytes in association with the systemic and leukocyte inflammatory profile. Atherosclerosis, 2018, 269, 236-244.	0.4	10
26	Podocyte endowment and the impact of adult body size on kidney health. American Journal of Physiology - Renal Physiology, 2021, 321, F322-F334.	1.3	10
27	Effects of pitavastatin add-on therapy on chronic kidney disease with albuminuria and dyslipidemia. Lipids in Health and Disease, 2015, 14, 161.	1.2	9
28	Effects of ATRAP in Renal Proximal Tubules on Angiotensinâ€Dependent Hypertension. Journal of the American Heart Association, 2019, 8, e012395.	1.6	9
29	Effects of Rikkunshito treatment on renal fibrosis/inflammation and body weight reduction in a unilateral ureteral obstruction model in mice. Scientific Reports, 2020, 10, 1782.	1.6	9
30	ATRAP Expression in Brown Adipose Tissue Does Not Influence the Development of Diet-Induced Metabolic Disorders in Mice. International Journal of Molecular Sciences, 2017, 18, 676.	1.8	8
31	Aging Vs. Hypertension: An Autopsy Study of Sclerotic Renal Histopathological Lesions in Adults With Normal Renal Function. American Journal of Hypertension, 2019, 32, 676-683.	1.0	8
32	Deficiency of the kidney tubular angiotensin II type1 receptor–associated protein ATRAP exacerbates streptozotocin-induced diabetic glomerular injury via reducing protective macrophage polarization. Kidney International, 2022, 101, 912-928.	2.6	8
33	Effect of single-pill irbesartan/amlodipine combination-based therapy on clinic and home blood pressure profiles in hypertension with chronic kidney diseases. Clinical and Experimental Hypertension, 2016, 38, 744-750.	0.5	7
34	Comparison of direct renin inhibitor and angiotensin II receptor blocker on clinic and ambulatory blood pressure profiles in hypertension with chronic kidney disease. Clinical and Experimental Hypertension, 2016, 38, 738-743.	0.5	6
35	Angiotensin II type 1 receptor-associated protein deficiency attenuates sirtuin1 expression in an immortalised human renal proximal tubule cell line. Scientific Reports, 2019, 9, 16550.	1.6	6
36	Nephron Number and Time to Remission in Steroid-Sensitive Minimal Change Disease. Kidney Medicine, 2020, 2, 559-568.e1.	1.0	6

3

#	Article	lF	CITATIONS
37	Within-visit blood pressure variability and cardiovascular risk factors in hypertensive patients with non-dialysis chronic kidney disease. Clinical and Experimental Hypertension, 2017, 39, 665-671.	0.5	5
38	Ambulatory blood pressure and tubulointerstitial injury in patients with IgA nephropathy. CKJ: Clinical Kidney Journal, 2015, 8, 716-721.	1.4	4
39	Circadian blood pressure abnormalities in patients with primary nephrotic syndrome. Clinical and Experimental Hypertension, 2017, 39, 155-159.	0.5	4
40	Relationship between basal sodium intake and the effects of dapagliflozin in albuminuric diabetic kidney disease. Scientific Reports, 2021, 11, 951.	1.6	4
41	Possible therapeutic impact of the iron chelation on renal fibrosis. Hypertension Research, 2015, 38, 455-456.	1.5	3
42	Possible interesting link between Janus kinase 2 mutation and renovascular hypertension. Journal of Clinical Hypertension, 2018, 20, 805-806.	1.0	3
43	Heterogeneous distribution of glomerular size in adult kidneys with normal renal function. Pathology International, 2018, 68, 500-501.	0.6	3
44	Effects of Erythropoietin-Stimulating Agents on Blood Pressure in Patients with Non-Dialysis CKD and Renal Anemia. Kidney Diseases (Basel, Switzerland), 2020, 6, 299-308.	1.2	3
45	Time-averaged proteinuria during follow-up and renal prognosis in patients with biopsy-proven benign nephrosclerosis. Clinical and Experimental Nephrology, 2020, 24, 688-695.	0.7	3
46	Total Nephron Number and Single-Nephron Parameters in Patients with IgA Nephropathy. Kidney360, 2021, 2, 828-841.	0.9	3
47	The ability of remaining glomerular podocytes to adapt to the loss of their neighbours decreases with age. Cell and Tissue Research, 2022, 388, 439-451.	1.5	3
48	Enhancement of intrarenal plasma membrane calcium pump isoform 1 expression in chronic angiotensin II-infused mice. Physiological Reports, 2017, 5, e13316.	0.7	2
49	Possible impact of electronegative LDL on atherosclerosis in type 2 diabetes. Atherosclerosis, 2017, 265, 253-255.	0.4	2
50	Tissue xanthine oxidoreductase activity in a mouse model of aristolochic acid nephropathy. FEBS Open Bio, 2021, 11, 507-518.	1.0	2
51	Tubulointerstitial nephritis: a biopsy case series of 139 Japanese patients. Clinical and Experimental Nephrology, 2022, 26, 435-444.	0.7	2
52	A Case of Hepatic Glomerulosclerosis with Monoclonal IgA1- <mml:math id="M1" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mrow><mml:mi>κ</mml:mi></mml:mrow></mml:math> Deposits. Case Reports in Nephrology, 2018, 2018, 1-5.	0.2	1
53	Remission of proteinuria under therapeutic intervention and the renal outcomes in Japanese patients with lupus nephritis class III and IV. Modern Rheumatology, 2020, 30, 125-131.	0.9	1
54	Two entities in pulmonary nodules of a diabetic patient receiving corticosteroid therapy for bullous pemphigoid: an autopsy case report. BMC Infectious Diseases, 2022, 22, .	1.3	1

#	Article	IF	CITATIONS
55	Potential beneficial impact of angiotensin receptor blockers on arterial stiffness in hypertension. Journal of Thoracic Disease, 2016, 8, E564-E566.	0.6	0